Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)

A regiszterben nem jelölt feltételek

• <Inclusion Criteria>
• Patients of 19 and over
• Patients with acute coronary syndrome treated with GENOSS SES
• Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants.
  • <Exclusion Criteria>
• Patients who are contraindicated in the use of heparin, aspirin, clopidogrel, sirolimus, cobalt chromium and contrast agents
  • However, patients with hypersensitivity to contrast agents may be eligible if it can be controlled by steroids and pheniramine. Patients with known anaphylaxis are excluded
• Patients who are pregnant or planning to become pregnant
• Patients scheduled to undergo surgery requiring the discontinuation of antiplatelet agents within 12 months from registration.
• Patients with a life expectancy of less than 1 year
• Patients who presented with cardiogenic shock at admission and are predicted to have a low chance of survival based on medical judgment.
• Patients who have already received treatment with another DES (Drug Eluting Stent), BVS (Bioresorbable Vascular Scaffolds), or BMS (Bare Metal Stent) at the time of registration.
• Patients currently participating in a randomized controlled trial involving medical devices.